Natera, Inc. $NTRA Shares Sold by E. Ohman J or Asset Management AB

E. Ohman J or Asset Management AB decreased its holdings in Natera, Inc. (NASDAQ:NTRA) by 8.1% during the 1st quarter, HoldingsChannel reports. The institutional investor owned 27,395 shares of the medical research company’s stock after selling 2,400 shares during the quarter. E. Ohman J or Asset Management AB’s holdings in Natera were worth $5,479,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of NTRA. BI Asset Management Fondsmaeglerselskab A S raised its stake in shares of Natera by 333.7% in the 1st quarter. BI Asset Management Fondsmaeglerselskab A S now owns 10,296 shares of the medical research company’s stock valued at $2,059,000 after acquiring an additional 7,922 shares during the period. Mozayyx Management LLC acquired a new position in shares of Natera during the 4th quarter valued at $309,000. Caitong International Asset Management Co. Ltd purchased a new stake in Natera during the 4th quarter worth $175,000. Reflection Asset Management purchased a new stake in Natera during the 4th quarter worth $29,000. Finally, Tobam raised its position in Natera by 24,935.0% in the fourth quarter. Tobam now owns 5,007 shares of the medical research company’s stock valued at $1,147,000 after purchasing an additional 4,987 shares during the period. 99.90% of the stock is owned by institutional investors and hedge funds.

Natera Price Performance

Shares of NTRA opened at $231.41 on Friday. The business’s fifty day moving average price is $208.20 and its 200 day moving average price is $215.52. Natera, Inc. has a 12-month low of $131.81 and a 12-month high of $256.36. The stock has a market capitalization of $33.14 billion, a PE ratio of -141.97 and a beta of 1.56.

Insider Activity

In other Natera news, Director Gail Boxer Marcus sold 11,000 shares of the stock in a transaction on Friday, June 5th. The shares were sold at an average price of $217.21, for a total transaction of $2,389,310.00. Following the sale, the director directly owned 6,183 shares of the company’s stock, valued at approximately $1,343,009.43. This represents a 64.02% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Rowan E. Chapman sold 2,964 shares of the firm’s stock in a transaction dated Tuesday, June 16th. The stock was sold at an average price of $216.78, for a total transaction of $642,535.92. Following the completion of the transaction, the director owned 3,124 shares in the company, valued at approximately $677,220.72. The trade was a 48.69% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 162,342 shares of company stock valued at $35,283,396 over the last quarter. 5.05% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of brokerages have commented on NTRA. BTIG Research reduced their price objective on Natera from $260.00 to $250.00 and set a “buy” rating on the stock in a research note on Monday, May 11th. Robert W. Baird set a $265.00 target price on Natera in a research note on Friday, May 8th. Piper Sandler reiterated an “overweight” rating and set a $249.00 target price on shares of Natera in a report on Tuesday, May 12th. Wells Fargo & Company boosted their price target on Natera from $215.00 to $220.00 and gave the stock an “equal weight” rating in a research report on Friday, May 8th. Finally, The Goldman Sachs Group initiated coverage on shares of Natera in a research report on Friday, June 5th. They issued a “neutral” rating and a $245.00 price objective for the company. Two research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $256.53.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.